High-dose chemotherapy (HDC) with autologous bone marrow transplant (ABMT) was a treatment developed in the 1980s[REF] but had its antecedents in 1957 when E. Donnall Thomas had shown that bone marrow could be harvested from a patient and transplanted into the same or another patient [REF].
In HDC, the bone marrow transplantation was used to maximise chemotherapeutic dosage.